2022
Endovascular Assessment of Liver Hemodynamics in Patients with Cirrhosis Complicated by Portal Hypertension
Ferral H, Schepis F, Gaba R, Garcia-Tsao G, Zanetto A, Perez-Campuzano V, Haskal Z, Garcia-Pagan J. Endovascular Assessment of Liver Hemodynamics in Patients with Cirrhosis Complicated by Portal Hypertension. Journal Of Vascular And Interventional Radiology 2022, 34: 327-336. PMID: 36516940, DOI: 10.1016/j.jvir.2022.12.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHepatic venous pressure gradientPortal hypertensionPortosystemic pressure gradientTransjugular intrahepatic portosystemic shuntVenous pressure gradientIntrahepatic portosystemic shuntSurgical patientsRisk stratificationHemodynamic measurementsPortosystemic shuntLiver hemodynamicsTreatment optionsShunt diameterMeticulous techniquePatientsClinical practiceGold standardHypertensionManagement optionsPressure gradientCirrhosisComplicatedHemodynamicsOptionsShunt
2012
Quantitative histological‐hemodynamic correlations in cirrhosis
Sethasine S, Jain D, Groszmann RJ, Garcia‐Tsao G. Quantitative histological‐hemodynamic correlations in cirrhosis. Hepatology 2012, 55: 1146-1153. PMID: 22109744, PMCID: PMC3721182, DOI: 10.1002/hep.24805.Peer-Reviewed Original ResearchConceptsSignificant portal hypertensionPortal hypertensionFibrosis areaLiver biopsyCirrhotic nodulesNodule sizeHVPG measurementPortal pressureIndependent predictorsSeptal thicknessFibrous septaBiopsyPathophysiological implicationsCirrhosisHVPGPatientsSemiquantitative analysisNodulesOnly parameterHypertensionNumber of nodules
2010
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis
Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia‐Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver International 2010, 30: 937-947. PMID: 20492521, DOI: 10.1111/j.1478-3231.2010.02272.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCirrhotic patientsHepatorenal syndrome type 2Transjugular intrahepatic portosystemic shuntEpisode of ascitesChronic renal insufficiencyLow sodium dietStandard medical treatmentIntrahepatic portosystemic shuntOccurrence of refractorinessCentral hypovolaemiaVasoconstrictor systemsArterial hypotensionDiuretic dosesLiver transplantationPortal hypertensionRefractory ascitesRenal insufficiencySodium dietSystemic haemodynamicsFrequent complicationSevere complicationsSerious complicationsSuch patientsPortosystemic shuntRenal sodium
2009
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis
Garcia‐Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology 2009, 51: 1445-1449. PMID: 20077563, PMCID: PMC2882065, DOI: 10.1002/hep.23478.Commentaries, Editorials and Letters
1991
Idiopathic portal hypertension.
Orozco H, Takahashi T, García-Tsao G, Mercado M, Diliz H, Hernández-Ortiz J. Idiopathic portal hypertension. Revista De Investigación Clínica 1991, 43: 80-6. PMID: 1866503.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIdiopathic portal hypertensionPortal hypertensionHigh re-bleeding rateMain histopathologic findingsNoncirrhotic portal fibrosisObliterative portal venopathySmall portal veinsRe-bleeding rateIntra-abdominal infectionsLong-term prognosisUpper gastrointestinal tractHepatitis B virusEsophago-gastric varicesChronic sclerotherapyHepatoportal sclerosisIPH patientsPortal venopathyPharmacologic managementVariceal bleedingCirrhotic patientsImmunologic abnormalitiesPortal fibrosisLiver failurePeriportal fibrosisSuch patients
1990
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage
Groszmann R, Bosch J, Grace N, Conn H, Garcia-Tsao G, Navasa M, Alberts J, Rodes J, Fischer R, Bermann M, Rofe S, Patrick M, Lerner E. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990, 99: 1401-1407. PMID: 2210246, DOI: 10.1016/0016-5085(90)91168-6.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientVenous pressure gradientVariceal hemorrhageEsophageal varicesHemodynamic eventsBaseline valuesHeart rateFirst variceal hemorrhagePropranolol-treated groupPropranolol-treated patientsTrial of propranololAdministration of propranololBeginning of therapyRate of survivalPortal hypertensionVariceal bleedingCirrhotic patientsPharmacological therapyVariceal sizeProtective effectMortality ratePatientsPlaceboPropranololVarices
1989
Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients
Vorobioff J, Garcia‐Tsao G, Groszmann R, Aceves G, Picabea E, Villavicencio R, Hernandez‐Ortiz J. Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients. Hepatology 1989, 9: 88-91. PMID: 2908873, DOI: 10.1002/hep.1840090114.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientPortal hypertensive patientsVenous pressure gradientMean arterial pressureHypertensive patientsCardiac indexArterial pressureMean baseline hepatic venous pressure gradientBaseline hepatic venous pressure gradientLong-term hemodynamic effectsAcute hemodynamic studyChronic oral administrationHepatic venous pressurePoor liver functionAlcoholic cirrhosisPortal hypertensionReceptor blockersHemodynamic effectsPortal pressurePortosystemic encephalopathyChronic treatmentVenous pressureLiver functionMean doseHemodynamic studies
1987
Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis Pharmacokinetic-hemodynamic interactions
Blei A, Garcia-Tsao G, Groszmann R, Kahrilas P, Ganger D, Morse S, Fung H. Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis Pharmacokinetic-hemodynamic interactions. Gastroenterology 1987, 93: 576-583. PMID: 3301517, DOI: 10.1016/0016-5085(87)90921-8.Peer-Reviewed Original ResearchConceptsIsosorbide dinitratePortal pressureArterial pressureHemodynamic changesHemodynamic evaluationHepatic vein wedge pressureHepatic venous gradientSystemic hemodynamic changesMean arterial pressureEffects of placeboValues 4 hStable cirrhoticsAlcoholic cirrhosisCardiac indexPortal hypertensionWedge pressureHemodynamic benefitsVenous gradientVasoactive metabolitesPharmacologic agentsIndividual patientsBaseline valuesExperimental animalsDinitratePatientsPortal hemodynamics during nitroglycerin administration in cirrhotic patients
Garcia‐Tsao G, Groszmann R. Portal hemodynamics during nitroglycerin administration in cirrhotic patients. Hepatology 1987, 7: 805-809. PMID: 3115881, DOI: 10.1002/hep.1840070502.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientVenous pressure gradientEffects of nitroglycerinMean arterial pressurePortal pressureArterial pressureNitroglycerin administrationBlood flowExperimental animalsAzygos blood flowPortal venous hemodynamicsPortal hypertensive patientsPortal blood flowVenous dilatorHypertensive patientsAlcoholic cirrhosisArterial vasodilatorCirrhotic patientsBlood pressurePortal hemodynamicsSublingual nitroglycerinVenous hemodynamicsHemodynamic responsePeak changesHeart rate
1986
Short‐term effects of propranolol on portal venous pressure
Garcia‐Tsao G, Grace N, Groszmann R, Conn H, Bermann M, Patrick M, Morse S, Alberts J. Short‐term effects of propranolol on portal venous pressure. Hepatology 1986, 6: 101-106. PMID: 3943775, DOI: 10.1002/hep.1840060119.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientVenous pressure gradientPropranolol plasma levelsHeart rateVenous pressurePlasma levelsMean baseline hepatic venous pressure gradientBaseline hepatic venous pressure gradientHepatic venous pressureBlood pressure responsePortal venous pressureEffect of propranololBaseline laboratoryAlcoholic cirrhosisPortal hypertensionPortal pressureLaboratory parametersLiver diseasePropranolol administrationAdditional dosesHemodynamic parametersOral administrationShort-term effectsPropranololPatients